FDA push­es back de­ci­sion on Zevra’s drug; Re­vance to raise $100M

Plus, news about Io­vance Bio­ther­a­peu­tics, Nek­tar Ther­a­peu­tics, Hei­del­berg Phar­ma, Vivory­on Ther­a­peu­tics and Ab­sci:

FDA de­lays de­ci­sion on Zevra Ther­a­peu­tics’ rare dis­ease drug: The FDA will …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER